menu
    • menu
    [{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"SPX-1009","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"TumorGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The Division of Cancer Treatment and Diagnosis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute","highestDevelopmentStatusID":"3","companyTruncated":"The Division of Cancer Treatment and Diagnosis \/ National Cancer Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by The Division of Cancer Treatment and Diagnosis

    Menu

    The Division of Cancer Treatment and Diagnosis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : TumorGen

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TumorGen Receives $390K NCI Grant to Counter Metastasis

                            Details : With this funding, the company will test the new technology in lung cancer patients, capturing metastatic cancer cell clusters (MCCCs) in their blood.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : TumorGen

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZEN-3694,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Zenith Epigenetics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

                            Details : First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.

                            Brand Name : ZEN-3694

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 05, 2020

                            Lead Product(s) : ZEN-3694,Nivolumab,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Zenith Epigenetics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            The Division of Cancer Treatment and Diagnosis

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-1009

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Sapphire Biotech

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Sapphire Biotech Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Insti...

                            Details : The grant will support the continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (“QSOX1”) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, in...

                            Brand Name : SPX-1009

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 11, 2020

                            Lead Product(s) : SPX-1009

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Sapphire Biotech

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth